🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease

Recruitingn/aAges 60 Years - anyAllHospices Civils de Lyon
NCT07409506 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system. Informal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation o

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients from Charpennes Hospital included in the MEM-AURA cohort * Patients aged 60 years and older at inclusion * Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage * Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion * Patients accompanied by a caregiver at inclusion Exclusion Criteria: * \- Patients or caregivers who have expressed their opposition to the study * Patients living in institutions or nursing homes * Patients protected by law (under legal protection, guardianship, or conservatorship) Early termination Criteria : \- Patients or caregivers withdrawing their consent to participate during the study
💊

What it tests

  • " Ressources Utilisation in Dementia " (RUD) questionnaire.
📍

Where

1 site
Hôpital des Charpennes
Villeurbanne, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy